High expression of monocarboxylate transporter 4 (MCT 4), but not MCT 1, predicts poor prognosis in patients with non-small cell lung cancer

doi:10.21037/tcr-20-3117

	High expression of monocarboxylate transporter 4 (MCT 4), but not MCT 1, predicts poor prognosis in patients with non-small cell lung cancer
	Tong, Ying-Hui 2; Hu, Xiao-Ping 1; Xiang, Xue-Ping 3; Fang, Luo 2
刊名	TRANSLATIONAL CANCER RESEARCH
	2021-03-01
卷号	10
关键词	Monocarboxylate transporter 1 (MCT1) monocarboxylate transporter 4 (MCT4) prognosis non-small cell lung cancer (NSCLC)
ISSN号	2218-676X
DOI	10.21037/tcr-20-3117
通讯作者	Xiang, Xue-Ping(xiangxueping@zju.edu.cn) ; Fang, Luo(Fangluo@zjcc.org.cn)
英文摘要	Background: The monocarboxylate transporter (MCT) family especially MCT1 and MCT4 have been recognized to play an important role in lactate transport, a key glycolytic product. The expression of MCT1 and MCT4 expression was previously found to be related to poor outcome in various cancer types. In this study, we investigated the expression status of MCT1 and MCT4 and their relationship with prognosis in non-small cell lung cancer (NSCLC). Methods: Expression of MCT4 and MCT1 in NSCLC tumor and adjacent lung tissues were detected by immunohistochemistry. Kaplan-Meier plots were used to evaluate two proteins' prognostic role, and the logrank test obtained the P value. For multivariate analysis, the Cox proportional-hazards regression method was performed. Results: High MCT4 and MCT1 expression was observed in cancer cells, with a rate of 45% for MCT4 versus 15% for MCT1 among all NSCLC patients. High expression of MCT4, and not MCT1, was associated with worse overall survival (OS) [hazard ratio (HR) =1.96 (1.06-3.75), P=0.032] and progressionfree survival (PFS) [HR =1.72 (1.05-2.93), P=0.032] in NSCLC patients. In our multivariate analysis, advanced cancer stage and high MCT4 level were identified as independent predictive indicators for both PFS [HR(MCT4) =1.888 (1.114-3.199), P=0.018 and OS [HR (MCT4) =2.421 (1.271-4.610), P=0.007]. Subgroup and interaction analyses were also performed in different clinical characteristic groups and no significant differences were observed. Conclusions: High MCT4 expression is a predictive marker for worse outcome in NSCLC patients.
资助项目	National Natural Science Foundation of China[81803549] ; Natural Science Foundation of Zhejiang Province[LQ18H310002] ; Projects of Medical and Health Technology Program in Zhejiang Province[2018253186] ; Projects of Medical and Health Technology Program in Zhejiang Province[2015KYB061]
WOS研究方向	Oncology
语种	英语
出版者	AME PUBL CO
WOS记录号	WOS:000635021300014
资助机构	National Natural Science Foundation of China ; Natural Science Foundation of Zhejiang Province ; Projects of Medical and Health Technology Program in Zhejiang Province
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/121594]
专题	中国科学院合肥物质科学研究院
通讯作者	Xiang, Xue-Ping; Fang, Luo
作者单位	1.Zhejiang Prov Peoples Hosp, Dept Pharm, Hangzhou, Peoples R China 2.Univ Chinese Acad Sci, Dept Pharm, Canc Hosp,Chinese Acad Sci, Zhejiang Canc Hosp,Inst Basic Med & Canc IBMC, Hangzhou, Peoples R China 3.Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Pathol, Hangzhou 310009, Peoples R China
推荐引用方式 GB/T 7714	Tong, Ying-Hui,Hu, Xiao-Ping,Xiang, Xue-Ping,et al. High expression of monocarboxylate transporter 4 (MCT 4), but not MCT 1, predicts poor prognosis in patients with non-small cell lung cancer[J]. TRANSLATIONAL CANCER RESEARCH,2021,10.
APA	Tong, Ying-Hui,Hu, Xiao-Ping,Xiang, Xue-Ping,&Fang, Luo.(2021).High expression of monocarboxylate transporter 4 (MCT 4), but not MCT 1, predicts poor prognosis in patients with non-small cell lung cancer.TRANSLATIONAL CANCER RESEARCH,10.
MLA	Tong, Ying-Hui,et al."High expression of monocarboxylate transporter 4 (MCT 4), but not MCT 1, predicts poor prognosis in patients with non-small cell lung cancer".TRANSLATIONAL CANCER RESEARCH 10(2021).